(MedPage Today) — LAS VEGAS — Upadacitinib (Rinvoq) showed durable clinical benefit at 1 year among children and adolescents with inflammatory bowel disease (IBD), a single-center study found.
In the retrospective study of 48 patients with…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.






